manufacture and commercialise the drug candidate “SON-080” for the treatment of diabetic peripheral neuropathy in India. According to a press statement, “SON-080” is Sonnet’s proprietary ...

Background: Identifying distinct mechanisms and biomarkers for painful diabetic peripheral neuropathy (DPN) is required for advancing the treatment of this major global unmet clinical need. We ...

(4) Denervated bands of Schwann cells. Multifocal diabetic neuropathy. Cross section of a paraffin-embedded superficial peroneal nerve specimen from a patient with a subacute progressive ...

Peripheral neuropathy is a serious complication ... There is currently no effective treatment for diabetic neuropathy, and good glycemic control is the only way to minimize the risk of occurrence ...

Neuro-immune interactions in specific contexts, such as diabetic and chemotherapy-induced peripheral neuropathy. 5. The impact of peripheral neuropathy-mediated ... Clinical trials and case studies ...

︎ Diabetic peripheral neuropathy, which affects about 30% of diabetics ... Beyond lifestyle modifications and keeping good control of your blood sugars, there are treatment options available to reduce ...

Mumbai: Alkem Laboratories Ltd. has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc to develop, manufacture and commercialise the drug candidate “SON-080” for the ...

for the research, development, manufacturing, marketing and commercialization of its molecule SON-080 for the treatment of diabetic peripheral neuropathy (DPN) in India. The agreement also ...

Peripheral neuropathy, a condition affecting millions of people worldwide, can cause chronic pain, numbness, and weakness, particularly in the hands and feet. While traditional treatments for ...

Alkem Laboratories Ltd. on Thursday announced that it has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings to develop, manufacture and commercialise its drug candidate ...